MedTrace Logo

Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction

NCT04610892 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 423

Last updated 2025-02-21

Study results available
· View outcomes & findings →

Summary

A Phase IIB Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction.

Conditions

  • Coronary Heart Disease (CHD)

Interventions

BIOLOGICAL

MEDI6570

MEDI6570

BIOLOGICAL

Placebo

Buffer

Sponsors & Collaborators

  • The TIMI Study Group

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-04
Primary Completion
2023-11-08
Completion
2023-11-08
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Czechia
  • Hungary
  • Italy
  • Japan
  • Netherlands
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04610892 on ClinicalTrials.gov